Why is it in the news?
→ Finance Minister announced Biopharma SHAKTI in Budget 2026–27.
→ Initiative launched to develop India as a global biopharma manufacturing hub.
Category
S&T
Important Points
- SHAKTI stands for Strategy for Healthcare Advancement through Knowledge, Technology & Innovation.
- The objective is to make India a global biopharmaceutical manufacturing hub.
- Builds ecosystem for domestic biologics and biosimilars.
- Includes network with 3 new NIPERs and upgrade of 7 existing NIPERs.
- Establishes over 1000 accredited India Clinical Trial sites.
- Financial outlay ₹10,000 crore over five years.
- Catalyses investment in advanced biomanufacturing infrastructure.
- Promotes innovation and next-generation therapies.
- Addresses rising non-communicable diseases like diabetes, cancer and autoimmune disorders.
- Biologics are complex medicines derived from living organisms.
- Biosimilars are highly similar versions of biologics ensuring therapeutic equivalence.